Monoclonal antibody · Inhibitor of Siglec-15 · developed by Pyxis Oncology
Aldastotug is a humanized monoclonal antibody that binds Siglec-15, a cell surface protein overexpressed on tumor-associated macrophages and certain tumor cells. It acts as an immune checkpoint inhibitor, intended to disrupt macrophage-mediated suppression of CD8 and CD4 T-cell responses. It is studied in solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05718557 | Phase 1 | Solid Tumor | Active not recruiting | PYXS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumor
See PYXS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PYXS catalysts and pipeline →